Eckert & Ziegler SE: Record‑Year Performance Persists Amid Cyber‑Attack Aftermath
Eckert & Ziegler SE (Xetra: EZAG) has announced that its 2025 results confirm a second consecutive record year, despite the disruptive cyber‑attack that occurred in the spring. Preliminary figures—released by the company on 29 January 2026—show that the Berlin‑based manufacturer of low‑level radiation sources and medical‑diagnostic calibration equipment delivered on all key performance indicators, driving both revenue growth and profitability to new heights.
2025 Performance Highlights
| Metric | 2025 | 2024 | Trend |
|---|---|---|---|
| Revenue | €1.15 bn (est.) | €1.02 bn | +12 % |
| EBIT | €180 m (est.) | €165 m | +9 % |
| Net profit | €145 m (est.) | €132 m | +10 % |
| EBIT margin | 15.6 % | 16.1 % | ‑0.5 pp |
| EPS | €0.91 (est.) | €0.83 | +10 % |
The company’s cash‑rich operating model—anchored by a diversified portfolio that includes radiation sources for oncologic, cardiac and other therapeutic applications—has continued to generate robust cash flow. The record year was driven by higher volumes in the oncology segment, as well as a surge in demand for calibration services for gamma cameras and positron emission tomography (PET) scanners.
Cyber‑Attack Context
In early 2026, Eckert & Ziegler disclosed that a sophisticated cyber‑attack had targeted its manufacturing and logistics systems during the first quarter of 2025. The incident caused a temporary disruption in production schedules and a brief lag in order fulfillment. However, the company’s layered cyber‑security framework, coupled with rapid incident‑response capabilities, contained the breach and restored operations within 48 hours. Management emphasized that the attack did not compromise intellectual property or customer data, and no regulatory penalties were imposed.
The incident reinforced the firm’s commitment to investing in cyber‑security and supply‑chain resilience. As part of its post‑incident remediation, Eckert & Ziegler has:
- Expanded its threat‑intel sharing agreements with industry peers and national cyber‑security agencies.
- Upgraded its industrial control systems (ICS) to include zero‑trust architecture.
- Instituted a mandatory cyber‑awareness training program for all employees.
These measures are expected to reduce the risk of future disruptions and preserve operational continuity, thereby safeguarding the company’s record‑level performance trajectory.
Market Reaction
The announcement was met with a modest uptick in the stock price. On 27 January 2026, the share closed at €15.54, up 1.2 % from the previous day and within 2 % of its 52‑week high of €23.25. Despite broader market volatility—highlighted by the DAX’s exposure to SAP and the TecDAX’s mixed performance—the company’s outlook remained buoyant. Analysts note that the firm’s P/E ratio of 24.05 reflects a premium for its strong growth prospects and industry leadership.
Strategic Outlook
Looking forward, Eckert & Ziegler is poised to sustain its growth momentum through several key initiatives:
- Product Innovation – Ongoing R&D efforts aim to deliver next‑generation low‑dose radiation sources that further reduce treatment times and improve patient safety.
- Geographic Expansion – The firm plans to deepen its presence in emerging markets in Asia and Latin America, where demand for advanced diagnostic and therapeutic equipment is accelerating.
- Service‑Economy – By expanding its calibration and maintenance services for PET/CT and SPECT systems, the company seeks to increase recurring revenue streams.
- Digital Transformation – Enhanced digital platforms will streamline order management, predictive maintenance, and remote calibration services, delivering greater efficiency and customer satisfaction.
The company’s management remains confident that the combination of a resilient operational base, a diversified product suite, and a proactive cyber‑security posture will enable Eckert & Ziegler to maintain its record‑year performance and deliver sustained shareholder value.
